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The natural host for Ebola virus, presumed to be an animal, has not yet been identified despite an extensive search
following several major outbreaks in Africa. A straightforward approach used to determine animal contact with Ebola virus
is by assessing the presence of specific antibodies in serum. This approach however has been made very difficult by the
absence of specific reagents required for the detection of antibodies from the majority of wild animal species. In this study,
we isolated a human monoclonal antibody Fab fragment, KZ51, that reacts with an immunodominant epitope on Ebola virus
nucleoprotein (NP) that is conserved on all four Ebola virus subtypes. The antibody KZ51 represents a major specificity as
sera from all convalescent patients tested (10/10) and sera from guinea pigs infected with each of the four Ebola virus
subtypes competed strongly with KZ51 for binding to radiation-inactivated Ebola virus. These features allowed us to develop
a novel assay for the detection of seroconversion irrespective of Ebola virus subtype or animal species. In this assay, the
binding of KZ51 Fab-phage particles is used as an indicator assay and the presence of specific antibodies against Ebola virus
in sera is indicated by binding competition. A prominent feature of the assay is that the Fab-phage particles may beINTRODUCTION
Infection with Ebola virus produces a hemorrhagic
fever in humans and certain nonhuman primates that is
associated with very high case-fatality rates (80–90% in
some outbreaks). Four subtypes of Ebola virus have
been described. Three subtypes, Ebola Zaire, Sudan,
and Ivory Coast, have been linked to infections in rain-
forests on the African continent. Ebola Zaire and Sudan
viruses are the most widespread and have been respon-
sible for all 1000 known lethal cases of Ebola virus
hemorrhagic fever in humans (Burton and Parren, 2000;
Sanchez et al., 2001; Wilson et al., 2001). Ebola Ivory
Coast virus was linked to a deadly epidemic among a
chimpanzee community in the rainforest of Ivory Coast.
The virus was transmitted to a researcher performing a
necropsy, who became severely ill but survived (For-
menty et al., 1999a,b). The fourth subtype, Ebola Reston
virus, has been found in monkeys imported into the
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236United States and Italy from an export facility in the
Philippines. The source of Ebola Reston virus infection of
the monkeys in this facility however remains unknown. A
number of animal care workers in the United States and
the Philippines seroconverted but did not become ill. In
contrast to the African Ebola viruses, Ebola Reston there-
fore does not appear to be pathogenic for humans (Rollin
et al., 1999; Miranda et al., 1999). The four Ebola virus
subtypes can be distinguished from each other on the
basis of serological, protein chemical, and molecular
biological techniques (Buchmeier et al., 1983; Feldmann
and Klenk, 1996; Sanchez et al., 1996). The glycoprotein
(GP) is the least conserved Ebola virus protein, differing
at 34–43% of amino acid positions between heterologous
subtypes (Sanchez et al., 1993; Sanchez et al., 1996;
Feldmann and Kiley, 1999). Comparisons of Ebola viruses
isolated from individuals at different time points in an
outbreak as well as viruses from the same subtype
isolated from distinct outbreaks have demonstrated a
remarkable sequence conservation. Thus, the Ebola
Zaire viral strain isolated in Yambuku, Democratic Re-
public of Congo (DRC) in 1976 differed at only 1.5% of GP
amino acids from the strain isolated in Kikwit, DRC in
1995, although almost two decades and a geographicalprestained with a dye so that detection of binding can be d
be both simple and economical to enable its use in the fie
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distance in excess of 600 miles separated these two
outbreaks (Sanchez et al., 1996, 1999).irectly
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Although Ebola virus hemorrhagic fever outbreaks
have been sporadic and relatively few people have died
from the disease compared to other more widespread
infectious diseases, the unpredictable, explosive, and
highly lethal nature of the disease has been disturbing. A
particular reason for concern has been the elusive na-
ture of the natural Ebola virus reservoir and possible
intermediate hosts. Small mammals, particularly bats,
are often considered the most likely reservoir based on
(1) in vitro and in vivo challenge studies (Swanepoel et
al., 1996; Turell et al., 1996); (2) theoretical considerations
such as similarities in proposed Ebola GP structure with
certain vertebrate RNA viruses (Gallaher, 1996; Weissen-
horn et al., 1998; Gallaher et al., 2001); and (3) the very
high level of GP glycosylation (Sanchez et al., 1998;
Feldmann et al., 1994) often linked to the evasion of
neutralizing antibody responses in higher animals. A
number of extensive field studies have been carried out
following outbreaks in the DRC and Sudan in 1976 and
again in the DRC in 1995 (Breman et al., 1999; Reiter et
al., 1999; Leirs et al., 1999). Literally thousands of animals
were collected and analyzed. Vertebrates were as-
sessed for the presence or contact history with Ebola
virus by virus isolation attempts and/or serological anal-
yses to detect the presence of Ebola virus antigens or
specific antibodies. All these tests have come up nega-
tive (Breman et al., 1999; Reiter et al., 1999; Leirs et al.,
1999). It is possible that the Ebola virus host or even
infection of the host is extremely rare and therefore,
despite all effort, infected animals have not been col-
lected. Alternatively, however, limitations of the assays
used may have made detection difficult. First, virus iso-
lation and antigen detection assays are unreliable for the
exclusion of certain species as possible hosts as the
virus may be sequestered or cleared from the circulation
and/or viral titers may be too low to detect with these
techniques. Second, serological assays suffer from the
paucity of specific reagents to detect antibodies in sera
from a wide range of wild animal species (Breman et al.,
1999).
To aid in the identification of anti-Ebola virus antibod-
ies in human and animal sera, we set out to design an
assay that would enable us to detect serum antibodies
against all four subtypes of Ebola virus independent of
the availability of reagents reactive with immunoglobu-
lins from a wide range of animals. The assay described
here is based on the human antibody KZ51, which reacts
with a conserved immunodominant epitope on NP.
RESULTS
Isolation of Ebola virus-specific Fab fragments
Antibody Fab fragment phage display libraries pre-
pared from bone marrows of two convalescent donors
(designated K and L) and from pooled PBMC from 10
convalescent donors (designated E10), who were in-
fected with Ebola Zaire virus during the 1995 outbreak in
Kikwit, DRC, have been described previously (Maruyama
et al., 1999a,b). Selection of these libraries against a
-irradiation-inactivated preparation of Ebola Zaire (May-
inga) virions yielded a panel of Fab fragments against
Ebola virus: two against NP, one against GP, and four
against sGP (Maruyama et al., 1999b). To obtain more
antibodies against Ebola virus, we prepared an addi-
tional library from the bone marrow of a rhesus macaque
(designated J3P) who survived a high-dose laboratory
challenge with Ebola Zaire virus. This library contained a
diversity of 1 106 clones and was also selected against
inactivated Ebola Zaire virus. Three novel Fab fragments
against Ebola virus were identified. One Fab (J3P-K14)
reacted strongly in ELISA with purified Ebola virions but
weakly with a crude Ebola virus-infected cell superna-
tant; the other two Fab fragments (J3P-K9 and -K11)
reacted relatively weakly with both these antigens (not
shown). These patterns of reactivity are characteristic for
antibodies against NP and GP, respectively (Maruyama
et al., 1999a). The reactivity of J3P-K14 with Ebola virus
NP was confirmed in Western blot (see below).
The deduced amino acid sequences for the variable
regions of light and heavy chains of the human and
monkey antibodies against NP have been submitted to
GenBank under Accession Nos. AY099259 through
AY099264. We aligned the antibodies with a human im-
munoglobulin gene database (http://imgt.cnusc.fr:8104/)
to determine the human germ-line genes most homolo-
gous to the sequences of these antibodies (Lefranc and
Lefranc, 2001). Comprehensive sequencing of immuno-
globulin variable region germ-line genes has not been
performed for rhesus macaques. However as there is
extensive sequence homology between humans and
monkeys (Lewis et al., 1993; Ermert et al., 1995; Glamann
et al., 1998), we have indicated the closest human germ-
line genes for comparison (Table 1). KZ51 and J3P-K14
are both IgG1, and ELZ510 is an IgG1,.
Identification of a broadly cross-reactive antibody
against Ebola NP
We have previously reported that Fab KZ51 and ELZ510
reacted with NP of Ebola Zaire (Maruyama et al., 1999b).
To investigate whether the antibodies against NP re-
acted with a conserved epitope, we now performed
Western blots with radiation-inactivated whole-virion
preparations of all four Ebola virus subtypes: Zaire, Ivory
Coast, Reston, and Sudan, as shown in Fig. 1. Interest-
ingly, Fab KZ51 reacted with a protein of 100 kDa MW,
corresponding to Ebola virus NP, from all four subtypes.
Staining of NP in Western blot was observed both with
purified KZ51 Fab fragment and with KZ51-phage (Fab
KZ51 displayed on the surface of filamentous phage
linked to the minor bacteriophage coat protein III) (Fig. 1;
Lanes 1 through 8). The monkey Fab J3P-K14, in contrast,
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was specific for NP of Ebola Zaire virus and did not bind
to NP from the remaining three subtypes (Fig. 1; Lanes 9
through 12). Radioimmunoprecipitation assays using ly-
sates of Vero E6 cells infected with each of the four
Ebola virus subtypes and metabolically labeled with
[35S]Cys-[35S]Met, confirmed the Western blot analysis. In
these assays, KZ51 immunoprecipitated a protein of
100 kDa MW for all Ebola virus-infected cells irrespec-
tive of subtype, but not from mock-infected cells. Fab
ELZ510 only precipitated NP from Ebola Zaire- and Ebola
Ivory Coast-infected cells (data not shown).
Detection of seroconversion against Ebola Zaire virus
in human sera using a Fab-phage competition ELISA
Our goal was to design an immunoassay which could
detect the presence of antibodies against Ebola virus
without the requirement for specific anti-antibody conju-
gates. We therefore set up a competition ELISA, in which
the binding of Fab KZ51-phage or Fab J3P-K14-phage to
immobilized Ebola Zaire virus NP was blocked by the
additional sera from Ebola Zaire virus-seropositive indi-
viduals. Binding of the Fab-phage particles was detected
with an HRPO-labeled sheep antibody against the M13
bacteriophage. The sera used in this analysis were de-
rived from 10 individuals who survived infection with
Ebola Zaire virus during the outbreak in Kikwit, DRC in
1995. The results shown in Fig. 2 demonstrate that all 10
sera tested competed for binding in ELISA with both
KZ51-phage and J3P-K14-phage and that competition
with KZ51-phage was superior to that of J3P-K14-phage.
TABLE 1
Determination of Germ-Line Gene Usagea
Antibody Isotype VH D JH VL JL
KZ51 IgG1,  IGHV1-2 cndb IGHJ6 IGKV3-11 IGKJ4
ELZ510 IgG1,  IGHV3-23 IGHD2-2 IGHJ4 IGLV1-47 IGLJ3
J3P-K14 (monkey)c IgG1,  IGHV4-59 cnd IGHJ4 IGKV1-39 IGKJ3
a The closest germ-line gene found in a database search (http://imgt.cnusc.fr:8104/) is shown.
b cnd, could not be determined.
c Ig germ-line genes have not been comprehensively sequenced for rhesus macaques. The genes with highest homology found in alignments with
the human repertoire are shown.
FIG. 1. Western blot of virions from the four Ebola virus subtypes
(Ebola Zaire, Ivory Coast, Reston, and Sudan) stained with purified Fab
KZ51 (Lanes 1–4), KZ51-phage (Lanes 5–8), and Fab J3P-K14 (Lanes
9–12). The relative molecular weights of marker proteins are shown in
kDa. The Fab fragments (KZ51 and J3P-K14) and the KZ51-phage were
stained with a goat anti-human F(ab)2-HRPO conjugate and a sheep
anti-M13-HRPO conjugate, respectively, followed by chemilumines-
cence substrate and exposure to photographic film.
FIG. 2. Competition ELISA of KZ51- and J3P-K14-phage with 10
human sera from persons who survived infection with Ebola Zaire virus.
Radiation-inactivated Ebola Zaire virions were coated on to the plate
and incubated with the human sera diluted 1:10 followed by KZ51-
phage of J3P-K14-phage. Following washing, bound Fab-phage was
detected using a sheep anti-M13-HRPO conjugate. Binding reduction
was determined as a percentage from wells incubated with Fab-phage
in the absence of human anti-Ebola virus antibody. K and L indicate
sera from the two individuals from whom antibody phage-display li-
braries have been prepared. The sera coded 95xxxxx are from individ-
uals who also survived infection with Ebola Zaire virus during the
outbreak in Kikwit, DRC. NHS indicates a representative normal human
control serum.
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Detection of seroconversion against Ebola virus in
animal sera using KZ51-phage competition ELISA
As the KZ51-phage behaved best in competition ELISA
with convalescent human sera (Fig. 2), and KZ51-phage
bound to NP from all four Ebola virus subtypes (Fig. 1),
we continued working with this phage exclusively. Figure
3 shows the results of a series of KZ51-phage competi-
tion ELISAs with sera derived from guinea pigs that each
survived infection with one of the four Ebola virus sub-
types. The sera from the guinea pigs infected with Ebola
Zaire, Reston, and Sudan all had high serum titers (as
defined as the serum dilution at which an ELISA sig-
nal 2  background was achieved) against the homol-
ogous virus in ELISA (1:50,000), whereas the serum
titer of the guinea pig infected with Ebola Ivory Coast
was lower (1: 2000). Competition ELISAs were carried
out for binding of KZ51-phage to immobilized inactivated
Ebola virus for all four subtypes with each serum (Fig. 3).
Figure 3 shows that sera from Ebola Zaire, Sudan, Ivory
Coast, and Reston virus-infected guinea pigs generally
compete well for KZ51-phage binding to Ebola virus irre-
spective of subtype immobilized on the plate. The only
exception is the antiserum against Ebola Reston virus
which reproducibly competes relatively weakly for bind-
ing of KZ51-phage to immobilized Ebola Zaire virus (44%
reduction in Fig. 3). Some reduction of KZ51-phage bind-
ing was observed in the presence of normal guinea pig
serum (23–27% in Fig. 3). To investigate whether this low
level of inhibition by nonimmune sera was a general
phenomenon, we performed competition experiments
with control sera from a number of species, including
guinea pig, goat, rabbit, and human. Some inhibition of
FIG. 4. PhAST immunoassay using red-colored KZ51-phage. (A) Bind-
ing of red-stained KZ51 phage to inactivated Ebola Zaire virus, BSA,
transferrin, and sheep anti-M13 immobilized on nitrocellulose circles.
(B) Competition PhAST immunoassay in which the binding of red
KZ51-phage to immobilized Ebola Zaire virus was inhibited with a
normal guinea pig serum, a guinea pig antiserum against Ebola Zaire,
and PBS. The fourth spot shows the binding of red KZ51-phage to
sheep anti-M13 as a positive control.
FIG. 3. Competition ELISA of KZ51-phage with sera from guinea pigs infected with Ebola virus subtypes. Radiation-inactivated Ebola virions (Sudan
(dark blue), Reston (red), Zaire (yellow), and Ivory coast (light blue) subtypes) were coated to the plate and incubated with the guinea pig sera diluted
1:10 followed by KZ51-phage. Following washing, bound KZ51-phage was detected using a sheep anti-M13-HRPO conjugate. Binding reduction was
determined as a percentage from wells incubated with KZ51-phage in the absence of guinea pig anti-Ebola virus antibody (shown on the vertical axis).
The specificity of the guinea pig antisera used is indicated on the front horizontal axis and the virions immobilized on the plate are indicated on the
right-hand-side horizontal axis. The data shown are representative for three independent competition experiments.
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KZ51-phage binding occurred with all these sera ranging
from a minimum of 7% for the human serum to a maxi-
mum of 27% for the guinea pig serum (data not shown).
Design of a competition assay using
a phage-antibody spot test (PhAST)
We set out to design an assay based on the Fab-phage
competition format described above that would be eco-
nomical and easy to use, so that it could be performed in
small laboratories or even in the field. As the Fab-phage
contain the genetic information for the Fab in their ge-
nome, they already provide for an unlimited and econom-
ical supply of the competition reagent. The detection
system used however provided a greater challenge. We
investigated a number methods of which an assay based
on Fab-phage particles directly stained with a dye ap-
peared the most promising. KZ51-phage were amplified
in Escherichia coli, PEG-precipitated, and then stained
red with the industrial textile dye Disperse Red 60. Com-
petition assays were then performed in a spot-test format
in which we spotted inactivated Ebola Zaire virus on
small pieces of nitrocellulose paper, which were then
sequentially incubated with specific antibodies and the
red-colored KZ51-phage particles. The results are shown
in Fig. 4. Direct red KZ51-phage staining of control anti-
gens immobilized on nitrocellulose is shown in Fig. 4A.
The red phage strongly stained the nitrocellulose filter
coated with inactivated Ebola Zaire virus and sheep
anti-M13 antibody, but not filters coated with control
antigens BSA or transferrin. Figure 4B shows the com-
petition PhAST assay with the red KZ51-phage again
strongly staining the immobilized radiation-inactivated
Ebola Zaire virus. This staining was inhibited with serum
from an Ebola Zaire virus-infected guinea pig, but not
with serum from a noninfected control animal. This
method should provide a rapid and low-cost procedure
to assess the presence of antibodies against Ebola virus
in the serum of any animal.
DISCUSSION
The search for the natural host of the filoviruses Ebola
virus and Marburg virus has been long and extensive but
unsuccessful (Breman et al., 1999; Leirs et al., 1999;
Reiter et al., 1999; Monath, 1999). This is of great concern
as prevention of filovirus infection by surveillance or
control of infected animals is thereby not feasible. There
have been a limited number of outbreaks of Ebola or
Marburg virus hemorrhagic fever over the years and only
a small number of people (compared with other major
pathogens such as HIV-1 and malaria) have died from
the disease (Burton and Parren, 2000). Some have ar-
gued that this class of viruses and disease associated
with infection have therefore gathered an undeserved
high level of attention. We believe however that it would
be prudent to be prepared for the possible occurrence of
larger and increased frequency of outbreaks. It should
be noted that the number of outbreaks has been on the
rise since the mid-1990s when outbreaks of Ebola Zaire
virus infections occurred in Gabon and the DRC followed
by two simultaneous outbreaks of filovirus hemorrhagic
fever, one with Marburg virus in the DRC and one with
Ebola Sudan virus in Uganda in the year 2000 (Burton
and Parren, 2000). A novel outbreak of Ebola virus hem-
orrhagic fever was confirmed in December 2001 in the
Ogooue Ivindo province of Gabon and neighboring DRC
(Leroy et al., 2002). It may be that humans encroach more
frequently on the habitat of the natural Ebola and Mar-
burg virus hosts. Such an increased sampling of filovi-
ruses from the wild may raise the concern that an out-
break would occur with a virus that is spread even more
easily between humans (for example, through aerosols).
Filoviruses may pose an additional threat, as there has
been concern that they might be employed in a bioter-
rorist attack. Identification of the natural host for these
viruses is therefore critical.
A problem with filovirus research is that all procedures
with specimens that potentially contain live virus, and
virus isolation procedures in particular, need to be per-
formed in biosafety level 4 facilities. The detection of
antibodies against filoviruses however can be performed
on inactivated sera in regular laboratory facilities and
therefore provide a much higher through-put assay for
the identification of animals that have been in contact
with a filovirus. It is highly problematic however to detect
the presence of specific antibodies in sera from a wide
range of wild animals. Protein A and G conjugates for
example are highly variable in their affinity for IgGs from
different species. Specific anti-antibody conjugates re-
quired for detection furthermore are not available for
many species (Breman et al., 1999). An additional com-
plicating factor is that, in particular for many small mam-
mal species, identification is difficult and not possible in
the field and may require sophisticated techniques (Leirs
et al., 1999).
In this study, we focused on Ebola virus which has
been responsible for most outbreaks and deaths due to
filovirus hemorrhagic fever. We designed an immunoas-
say that can detect antibodies against the conserved
Ebola virus protein NP in animal sera and determine
seroconversion irrespective of Ebola virus subtype or
animal species. The epitope recognized by the antibody
against NP, mAb KZ51, recognizes a highly conserved
epitope which is expressed on all four known subtypes
of Ebola virus. The epitope also appears to be immuno-
dominant as strong competition for binding to immobi-
lized NP was observed with sera from 10/10 human
donors who survived infection with Ebola Zaire and sera
from guinea pigs infected with each of the four Ebola
virus subtypes. We can of course not be certain that the
natural Ebola virus host would also mount a strong
response against this epitope, but the strong competition
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observed with sera from both infected humans and in-
fected guinea pigs at least makes this likely.
The competition assay described in this study was
designed as a diagnostic rather than a quantitative tool.
Particularly the PhAST assay may be useful to test large
numbers of animals directly in the field or in local African
laboratories. The production of the KZ51-phage and
staining with the red dye is straightforward and econom-
ical. A low level of background inhibition was observed
when sera from uninfected animals were tested. It would
therefore appear prudent to establish a cutoff value of
50% or greater inhibition before a sample is considered
positive. Positive samples should furthermore be sent to
reference laboratories for confirmation. A caveat of the
assay described is that we used an irradiation-inacti-
vated preparation of Ebola virions as a source for NP.
However, recombinant Ebola NP has recently been suc-
cessfully produced in E. coli (Prehaud et al., 1998) and
baculovirus (Niikura et al., 2001), which may provide
good, and probably superior, alternatives to the inacti-
vated virion preparations used here.
MATERIALS AND METHODS
Phage libraries and antibodies
Antibody phage-display libraries prepared from bone
marrow from donors K and L who recovered from infec-
tion with Ebola Zaire virus during the 1995 outbreak in
Kikwit, DRC have been described previously. A third
phage-display library was prepared from pooled RNA
prepared from PBMC from 10 survivors from this out-
break (Maruyama et al., 1999a,b). The isolation of anti-
Ebola virus Zaire NP Fabs KZ51 and ELZ510 has been
described in Maruyama et al. (1999a,b).
Sera
Sera from 10 convalescent individuals from Kikwit,
DRC, who recovered from Ebola hemorrhagic fever, were
drawn between 5 and 8 July 1995. Sera from guinea pigs
that survived infection with Ebola Zaire virus, Ebola Su-
dan virus, Ebola Ivory Coast virus, and Ebola Reston
virus were prepared in the BSL4 facility at USAMRIID.
The animals were challenged i.m. with 1000 PFU of each
virus and serum was drawn 1 month later.
Library construction
A phage-display library was prepared from the bone
marrow of a rhesus macaque (designated J3P) that sur-
vived challenge with Ebola Zaire virus after treatment
with a Factor XIIa antagonist and developed a relatively
high neutralizing serum titer against Ebola Zaire virus
(IC80  1:80). Library construction in the phagemid vector
pComb3H was performed as detailed previously (Gla-
mann et al., 1998; Maruyama et al., 1999b).
Affinity selection of phage-display libraries
A -irradiated Ebola Zaire 1976 whole-virion prepara-
tion (inactivated by applying 2  106 rad of -radiation to
a frozen sample) was used for selection as described
previously (Maruyama et al., 1999b) or Ebola virus GP
was captured on immobilized wheat germ agglutinin
(Sigma). The library was panned for four consecutive
rounds of selection with increasing washing stringency
(2, 5, and 10 wash steps thereafter, each consisting of a
5-min incubation and vigorous pipetting). After the last
round of panning, colonies were picked, expanded, and
phage isolated. Specific binders were identified in phage
ELISA. To prepare soluble Fab, phagemid DNA was
isolated, digested with NheI and SpeI restriction endo-
nucleases to excise the cpIII gene, re-ligated, and used
to transform E. coli.
Preparation of Fab-phage
Pcomb3H phagemid DNA containing the genetic infor-
mation for the desired Fab fragment were used to trans-
form E. coli XL1 blue (Stratagene, La Jolla, CA) and plated
on LB plates containing carbenicillin (100 g/ml) (for
media recipes, see Barbas et al., 2001). Starting from a
single colony, 10 ml cultures were grown in superbroth
(SB) medium supplemented with tetracycline (10 g/ml)
and carbenicillin (50 g/ml) for about 6 h at 37°C while
shaking (250 rpm) to an OD600 of 0.8. VCS M13 helper
phage (1012) (Stratagene) was added to the culture, and
the culture volume was increased to 100 ml. IPTG
(Sigma, St. Louis, MO) was added to a final concentration
of 10 M, and the culture grown for 2 h at 37°C while
shaking (300 rpm). Kanamycin was added to a final
concentration of 70 g/ml and the culture grown over-
night at 30°C (300 rpm). The next day, the cells were
pelleted by a 30-min centrifugation at 4000 g at 4°C. The
supernatant was immediately aliquoted and frozen at
80°C. These Fab-phage preparations were used for
competition ELISAs with sheep anti-M13-HRPO conju-
gate detection (described below).
Western blot
Western blotting was performed as described previ-
ously (Hansen et al., 2001) except that blots were incu-
bated with Fab KZ51 (10 g/ml), Fab J3P-K14 (10 g/ml),
or KZ51-phage (1:12.5) (each diluted in PBS/0.05% Tween
20) and detection was performed using goat anti-human
IgG F(ab)2-HRPO conjugate (Pierce) diluted 1:5000 in
PBS/0.05% Tween 20 or anti-M13 phage-HRPO conju-
gate; Amersham Pharmacia, Uppsala, Sweden) diluted
1:3000 in PBS/0.05% Tween 20.
Competition ELISA
Competition ELISA was essentially performed as de-
scribed by Ditzel et al. (1995).
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Preparation of red-colored Fab-phage
Fab-phage was prepared as described above, after
which the phage was concentrated by PEG precipitation.
After clarifying the bacterial supernatant by centrifuga-
tion at 4000 g, phage were precipitated by addition of
polyethylene glycol 8000 to a concentration of 4% (w/v)
and NaCl to a final concentration of 0.5 M. The mixture
was incubated on ice for 30 min, followed by centrifuga-
tion at 8000 g. Phage was dissolved in 1 ml PBS and
mixed with an equal volume of Disperse Red dye, which
was prepared as described below, and incubated for 1 h
at room temperature with occasional shaking. A 1/5
volume of a 30% BSA solution in PBS (pH 7.4) was added
to stabilize the dye-particle surfaces and incubated for
another 30 min at room temperature. The mixture was
then centrifuged at 5000 g for 30 min and the pellet
resuspended in 1 ml PBS containing 1% BSA and 0.02%
Tween 20. The red-colored phage particles were used
for the dip-stick competition assays.
The red dye was prepared by dispersing 5% (w/v) of
the dye Disperse Red 60 (200%) (Organic Dyestuffs
Corp., East Providence, RI) in PBS, followed by centrifu-
gation at 20,000 g for 30 min. The pellet was resus-
pended in PBS and again centrifuged. After repeating
this procedure a total of four times, the dye was spun one
last time at low speed (125 g) for 1 h to remove aggre-
gates. The supernatant was used for staining of Fab-
phage particles as described above.
Phage-antibody spot test
Antigen assay. Nitrocellulose circles were prepared by
punching 7-mm-diameter circles from a strip of nitrocel-
lulose membrane (Bio-Rad, Hercules, CA) using a hole
puncher. A 3-l spot of each antigen was added directly
to the membrane and the membrane was allowed to air
dry at room temperature (RT) for 10 min. The antigens
included the following: inactivated Ebola Zaire (1:10 in
PBS), BSA (30 mg/ml in PBS), transferrin (200 g/ml in
PBS), and sheep anti-M13 (1:500 in PBS) (Amersham
Pharmacia). The membrane was then immersed in 4%
nonfat dry milk for blocking at RT for 20 min followed by
air drying for 10 min. The membranes were transferred
into a solution of red-colored Fab KZ51-phage for 1 h at
RT, washed with PBS/0.05% Tween 20, allowed to dry,
and observed for red staining.
Competition assay. Nitrocellulose membrane circles
as prepared above and a 10 l spot of inactivated Ebola
Zaire virus was spotted and allowed to air dry for 10 min
at RT. The nitrocellulose circles were placed into the
wells of a 48-well microtiter plate. Serum from a nonin-
fected and an Ebola Zaire virus-infected guinea pig were
diluted 1:2 in PBS and 10 l was added to the mem-
branes. A control membrane coated with Ebola Zaire
antigen was incubated with PBS. A second control mem-
brane coated with anti-M13 antibody (diluted 1:500 in
PBS) was also incubated with PBS. All membranes were
incubated for 1 h at RT after which 50 l of red-colored
Fab-phage particles were added and incubated over-
night at RT with gentle shaking. The membranes were
then washed with PBS/0.05% Tween, allowed to air dry,
and observed for staining.
ACKNOWLEDGMENTS
We thank Joan Geisbert for expert technical assistance and Aran
Labrijn for helpful suggestions. This work was supported in part by NIH
Grant AI48053 (to D.R.B.).
REFERENCES
Barbas, C. F., III, Burton, D. R., Scott, J. K., and Silverman, G. J. (2001).
“Phage Display: A Laboratory Manual.” Cold Spring Harbor Labora-
tory Press, Cold Spring Harbor, New York.
Breman, J. G., Johnson, K. M., van der Grown, G., Robbins, C. B.,
Szczeniowski, M. V., Ruti, K., Webb, P. A., Meier, F., Heymann, D. L.,
and Ebola Virus Study Teams. (1999). A search for Ebola virus in
animals in the Democratic Republic of the Congo and Cameroon:
Ecologic, virologic, and serologic surveys, 1979–1980. J. Infect. Dis.
S179, S139–S147.
Buchmeier, M. J., DeFries, R., McCormick, J. B., and Kiley, M. P. (1983).
Comparative analysis of the structural polypeptides of Ebola virus
from Sudan and Zaire. J. Infect. Dis. 147, 276–281.
Burton, D. R., and Parren, P. W. H. I. (2000). Fighting the Ebola virus.
Nature 408, 527–528.
Ditzel, H. J., Binley, J. M., Moore, J. P., Sodroski, J., Sullivan, N., Sawyer,
L. S. W., Hendry, R. M., Yang, W. P., Barbas, C. F., III, and Burton, D. R.
(1995). Neutralizing recombinant human antibodies to a conforma-
tional V2- and CD4-binding site-sensitive epitope of HIV-1 gp120
isolated by using an epitope-masking procedure. J. Immunol. 154,
893–906.
Ermert, K., Mitlohner, H., Schempp, W., and Zachau, H. G. (1995). The
immunoglobulin kappa locus of primates. Genomics 25, 623–629.
Feldmann, H., and Kiley, M. P. (1999). Classification, structure, and
replication of filoviruses. Curr. Top. Microbiol. Immunol. 235, 1–21.
Feldmann, H., and Klenk, H.-D. (1996). Marburg and Ebola viruses. Adv.
Virus Res. 47, 1–52.
Feldmann, H., Nichol, S. T., Klenk, H.-D., Peters, C. J., and Sanchez, A.
(1994). Characterization of filoviruses based on differences in struc-
ture and antigenicity of the virion glycoprotein. Virology 199, 469–
473.
Formenty, P., Boesch, C., Wyers, M., Steiner, C., Donati, F., Dind, F.,
Walker, F., and Le Guenno, B. (1999a). Ebola virus outbreak among
wild chimpanzees living in a rain forest of Coˆte d’Ivoire. J. Infect. Dis.
179(Suppl. 1), S120–S126.
Formenty, P., Hatz, C., Le Guenno, B., Stoll, A., Rogenmoser, P., and
Widmer, A. (1999b). Human infection due to Ebola virus, subtype Coˆte
d’Ivoire: Clinical and biologic presentation. J. Infect. Dis. 179(Suppl.
1), S48–S53.
Gallaher, W. R. (1996). Similar structural models of the transmembrane
proteins of Ebola and avian sarcoma viruses. Cell 85, 477–478.
Gallaher, W. R., DiSimone, C., and Buchmeier, M. J. (2001). The viral
transmembrane superfamily: Possible divergence of arenavirus and
filovirus glycoproteins from a common RNA virus ancestor. BMC
Microbiol. 1, 1.
Glamann, J., Burton, D. R., Parren, P. W. H. I., Ditzel, H. J., Kent, K. A.,
Arnold, C., Montefiori, D., and Hirsch, V. M. (1998). Simian immuno-
deficiency virus (SIV) envelope-specific Fabs with high-level homol-
ogous neutralizing activity: Recovery from a long-term-nonprogres-
sor SIV-infected macaque. J. Virol. 72, 585–592.
Hansen, M. H., Nielsen, H., and Ditzel, H. J. (2001). The tumor filtrating
242 MEISSNER ET AL.
B cell response in medullary breast cancer is oligoclonal and di-
rected against an intracellular antigen exposed on the surface of
apoptotic cancer cells. Proc. Natl. Acad. Sci. USA 98, 12659–12664.
Lefranc, M.-P., and Lefranc, G. (2001). “The Immunoglobulin Factsbook.”
Academic Press, San Diego.
Leirs, H., Mills, J. N., Krebs, J. W., Childs, J. E., Akaibe, D., Woollen, N.,
Ludwig, G., Peters, C. J., Ksiazek, T. G., et al. (1999). Search for the
ebola virus reservoir in Kikwit, Democratic Republic of the Congo:
Reflections on a vertebrate collection. J. Infect. Dis. S179, S155–S163.
Leroy, E. M., Souquiere, S., Rouquet, P., Drevet, D. (2002). Re-emer-
gence of Ebola haemorrhagic fever in Gabon. Lancet 359, 712.
Lewis, A. P., Barber, K. A., Cooper, H. J., Sims, M. J., Worden, J., and
Crowe, J. S. (1993). Cloning and sequencing analysis of kappa and
gamma cynomolgus monkey immunoglobulin cDNAs. Dev. Comp.
Immunol. 17, 549–560.
Maruyama, T., Parren, P. W. H. I., Sanchez, A., Rensink, I., Rodriguez,
L. L., Khan, A., Peters, C. J., and Burton, D. R. (1999a). Recombinant
human monoclonal antibodies to Ebola virus. J. Infect. Dis. 179,
S235–S239.
Maruyama, T., Rodriguez, L. L., Jahrling, P. B., Sanchez, A., Khan, A. S.,
Nichol, S. T., Peters, C. J., Parren, P. W. H. I., and Burton, D. R. (1999b).
Ebola virus can be effectively neutralized by antibody produced in
natural human infection. J. Virol. 73, 6024–6030.
Miranda, M. E., Ksiazek, T. G., Retuya, T. J., Khan, A. S., Sanchez, A.,
Fulhorst, C. F., Rollin, P. E., Calaor, A. B., Manalo, D. L., Roces, M. C.,
Dayrit, M. M., and Peters, C. J. (1999). Epidemiology of Ebola (subtype
Reston) virus in the Philippines, 1996. J. Infect. Dis. 179(Suppl. 1),
S115–S119.
Monath, T. P. (1999). Ecology of Marburg and Ebola viruses: Specula-
tions and directions for future research. J. Infect. Dis. 179(Suppl. 1),
S127–S138.
Niikura, M., Ikegami, T., Saijo, M., Kuran, I., Miranda, M. E., and
Morikawa, S. (2001). Detection of Ebola viral antigen by enzyme-
linked immunosorbent assay usning a novel monoclonal antibody to
nucleoprotein. J. Clin. Microbiol. 39, 3267–3271.
Prehaud, C., Hellebrand, E., Coudrier, D., Volchkov, V. E., Volchkova,
V. A., Feldmann, H., Le Guenno, B., and Boulou, M. (1998). Recombi-
nant Ebola virus nucleoprotein and glycoprotein (gabon 94 strain)
provide new tools for the detection of human infections. J. Gen. Virol.
79, 2565–2572.
Reiter, P., Turell, M., Coleman, R., Miller, B., aupin, G., Liz, J., Kuehne,
A., Barth, J., Geisbert, J., Dohm, D., Glick, J., Pecor, J., Robbins, R.,
Jahrling, P., Peters, C., and Ksiazek, T. (1999). Field investigations of
an outbreak of Ebola hemorrhagic fever, Kikwit, Democratic Republic
of the Congo, 1995: Arthropod studies. J. Infect. Dis. S179, S148–
S154.
Rollin, P. E., Williams, R. J., Bressler, D. S., Pearson, S., Cottingham, M.,
Pucak, G., Sancheze, A., Trappier, S. G., Peters, R. L., Greer,
P. W. Z. S., Demarcus, T., Hendricks, K., Kelley, M., Simpson, D.,
Geisbert, T. W., Jahrling, P. B., Peters, C. J., and Ksiazek, T. G. (1999).
Ebola (subtype Reston) virus among quarantined nonhuman pri-
mates recently imported from the Philippines to the United States.
J. Infect. Dis. 179(Suppl. 1), S108–S114.
Sanchez, A., Khan, A. S., Zaki, S. R., Nabel, G. J., Ksiazek, T. G., and
Peters, C. J. (2001). Filoviridae: Marburg and Ebola viruses. In “Fields
Virology.” pp. 1279–1304. Lippincott Williams & Wilkins, Philadelphia,
PA.
Sanchez, A., Kiley, M. P., Holloway, B. P., and Auperin, D. D. (1993).
Sequence analysis of the Ebola virus genome: Organization, genetic
elements, and comparison with the genome of Marburg virus. Virus
Res. 29, 215–240.
Sanchez, A., Ksiazek, T. G., Rollin, P. E., Miranda, M. E. G., Trappier,
S. G., Khan, A. S., Peters, C. J., and Nichol, S. T. (1999). Detection and
molecular characterization of Ebola viruses causing diseas in human
and nonhuman primates. J. Infect. Dis. S179, S164–S169.
Sanchez, A., Trappier, S. G., Mahy, B. W. J., Peters, C. J., and Nichol, S. T.
(1996). The virion glycoproteins of Ebola viruses are encoded in two
reading frames and are expressed through transcription editing.
Proc. Natl. Acad. Sci. USA 93, 3602–3607.
Sanchez, A., Yang, Z. Y., Xu, L., Nabel, G. J., Crews, T., and Peters, C. J.
(1998). Biochemical analysis of the secreted and virion glycoproteins
of Ebola virus. J. Virol. 72, 6442–6447.
Swanepoel, R., Leman, P. A., Burt, F. J., Zachariades, N. A., Braack, L. E.,
Ksaizek, T. G., Rollin, P. E., Zaki, S. R., and Peters, C. J. (1996).
Experimental inoculation of plants and animals with Ebola virus.
Emerg. Infect. Dis. 2, 321–325.
Turell, M. J., Bressler, D. S., and Rossi, C. A. (1996). Lack of virus
replication in arthropods after intrathoracic inoculation of Ebola Re-
ston virus. Am. J. Trop. Med. Hyg. 55, 89–90.
Weissenhorn, W., Carfi, A., Lee, K. H., Skehel, J. J., and Wiley, D. C.
(1998). Crystal structure of the Ebola virus membrane fusion subunit,
GP2, from the envelope glycoprotein ectodomain. Mol. Cell 2, 605–
616.
Wilson, J. A., Bosio, C. M., and Hart, M. K. (2001). Ebola virus: The
search for vaccines and treatments. Cell. Mol. Life Sci. 58, 1826–1841.
243DETECTION OF ANTIBODIES AGAINST EBOLA VIRUS
